BRPI0807828B8 - composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras - Google Patents

composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras

Info

Publication number
BRPI0807828B8
BRPI0807828B8 BRPI0807828A BRPI0807828A BRPI0807828B8 BR PI0807828 B8 BRPI0807828 B8 BR PI0807828B8 BR PI0807828 A BRPI0807828 A BR PI0807828A BR PI0807828 A BRPI0807828 A BR PI0807828A BR PI0807828 B8 BRPI0807828 B8 BR PI0807828B8
Authority
BR
Brazil
Prior art keywords
yeasts
growing
kit
composition
well
Prior art date
Application number
BRPI0807828A
Other languages
English (en)
Inventor
Franzusoff Alex
Quick Deborah
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of BRPI0807828A2 publication Critical patent/BRPI0807828A2/pt
Publication of BRPI0807828B1 publication Critical patent/BRPI0807828B1/pt
Publication of BRPI0807828B8 publication Critical patent/BRPI0807828B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras . a invenção fornece métodos para o cultivo de leveduras em um nível de ph neutro. as leveduras cultivadas sob condições de ph neutro exibem características desejáveis úteis para fins biológicos como, por exemplo, o desenvolvimento de vacinas, substâncias profiláticas e terapêuticas. a invenção também fornece composições e kits que compreendem leveduras desenvolvidas com o uso das metodologias aqui reveladas.
BRPI0807828A 2007-02-02 2008-02-01 composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras BRPI0807828B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89928107P 2007-02-02 2007-02-02
US60/899,281 2007-02-02
PCT/US2008/052843 WO2008097863A2 (en) 2007-02-02 2008-02-01 Methods for producing yeast-based vaccines

Publications (3)

Publication Number Publication Date
BRPI0807828A2 BRPI0807828A2 (pt) 2014-08-05
BRPI0807828B1 BRPI0807828B1 (pt) 2018-05-29
BRPI0807828B8 true BRPI0807828B8 (pt) 2021-05-25

Family

ID=39682350

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807828A BRPI0807828B8 (pt) 2007-02-02 2008-02-01 composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras

Country Status (17)

Country Link
US (2) US9066893B2 (pt)
EP (1) EP2121013B1 (pt)
JP (2) JP5570819B2 (pt)
KR (2) KR20150006022A (pt)
CN (2) CN104120086A (pt)
AU (1) AU2008214029B2 (pt)
BR (1) BRPI0807828B8 (pt)
CA (1) CA2676783C (pt)
DK (1) DK2121013T3 (pt)
ES (1) ES2527756T3 (pt)
IL (2) IL200176A (pt)
MX (1) MX2009008175A (pt)
PL (1) PL2121013T3 (pt)
PT (1) PT2121013E (pt)
SG (2) SG10201405420QA (pt)
SI (1) SI2121013T1 (pt)
WO (1) WO2008097863A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
EP2004666B1 (en) 2006-03-27 2014-09-03 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
EP2121013B1 (en) * 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
CA2681246A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
SG193396A1 (en) 2011-03-17 2013-10-30 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
WO2012174220A1 (en) 2011-06-14 2012-12-20 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
RU2642300C2 (ru) 2011-08-17 2018-01-24 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
KR20150132867A (ko) 2013-03-19 2015-11-26 글로브이뮨 척색종에 대한 효모-기반의 면역치료
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン，インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
CN112543640B (zh) * 2018-05-15 2025-02-14 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
WO2020061203A1 (en) 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
JP3510639B2 (ja) * 1991-06-28 2004-03-29 カルピス株式会社 インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品
JP3091851B2 (ja) 1992-11-06 2000-09-25 工業技術院長 哺乳類の高マンノース型糖蛋白質糖鎖の酵母による製造法
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP0974665A4 (en) * 1997-02-07 2003-02-05 Oriental Yeast Co Ltd RECOMBINANT PDI FROM YEAST AND METHOD FOR THE PRODUCTION THEREOF
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4288862B2 (ja) * 2001-03-30 2009-07-01 トヨタ自動車株式会社 プレニルアルコールの製造方法
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR100507665B1 (ko) 2003-03-25 2005-08-10 김경숙 페리틴 이형집합체를 효모 내에서 발현시키기 위한 벡터 및 상기 발현벡터로 형질전환 시킨 재조합 효모
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4904086B2 (ja) * 2005-05-25 2012-03-28 公益財団法人微生物化学研究会 クラゲ類の分解廃液の処理装置及び処理方法、並びに微生物
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
KR20140029551A (ko) * 2006-02-02 2014-03-10 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
EP2004666B1 (en) 2006-03-27 2014-09-03 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
EP2121013B1 (en) 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
CA2681246A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en) 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy

Also Published As

Publication number Publication date
AU2008214029A1 (en) 2008-08-14
SG171577A1 (en) 2011-06-29
HK1136979A1 (en) 2010-07-16
CA2676783C (en) 2016-04-05
KR101555641B1 (ko) 2015-09-24
PT2121013E (pt) 2015-02-04
IL200176A (en) 2015-10-29
MX2009008175A (es) 2009-08-12
JP5570819B2 (ja) 2014-08-13
JP2014223072A (ja) 2014-12-04
IL237406A0 (en) 2015-04-30
US20130309269A1 (en) 2013-11-21
AU2008214029B2 (en) 2014-01-30
EP2121013A2 (en) 2009-11-25
BRPI0807828A2 (pt) 2014-08-05
US9066893B2 (en) 2015-06-30
US9549970B2 (en) 2017-01-24
ES2527756T3 (es) 2015-01-29
KR20150006022A (ko) 2015-01-15
CA2676783A1 (en) 2008-08-14
US20100189749A1 (en) 2010-07-29
WO2008097863A2 (en) 2008-08-14
CN104120086A (zh) 2014-10-29
SI2121013T1 (sl) 2015-02-27
BRPI0807828B1 (pt) 2018-05-29
EP2121013B1 (en) 2014-10-15
WO2008097863A3 (en) 2008-11-20
KR20090116757A (ko) 2009-11-11
CN101687030B (zh) 2014-07-02
IL200176A0 (en) 2010-04-15
PL2121013T3 (pl) 2015-05-29
CN101687030A (zh) 2010-03-31
JP2010517537A (ja) 2010-05-27
SG10201405420QA (en) 2014-10-30
DK2121013T3 (en) 2015-01-19

Similar Documents

Publication Publication Date Title
MX2009008175A (es) Metodos para producir vacunas basadas en levadura.
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
CR9551A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
BRPI0516323A (pt) construtos de rna
BRPI0916121A8 (pt) métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição
MX2010010600A (es) Composiciones y metodos para secuenciacion de acidos nucleicos.
CR8257A (es) Construcciones de union y metodos para uso de ellas
PT2752484T (pt) Método para preparar um meio de cultura básico para células estaminais mesenquimais, meio de cultura básico para células estaminais mesenquimais, e agente terapêutico celular cultivado e diferenciado usando o mesmo
AR066395A1 (es) Reovirus que tienen secuencias modificadas
AR053906A1 (es) Metodos para incrementar la resistencia de las plantas a condiciones hipoxicas
BRPI0611863A2 (pt) composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo
BR112018015312A2 (pt) cepa fúngica isolada, cultura biologicamente pura, composição inoculante, kit, uso de uma cepa, e, método para aumentar quantidade/concentração de fosfato solúvel em um meio que contém fosfato insolúvel
WO2007008722A3 (en) Method for the isolation of rna from biological sources
AR058986A1 (es) Dominios de epsp sintetasa que confieren resistencia al glifosato
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
NO20070746L (no) Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket.
AR114504A1 (es) Regeneración de plantas genéticamente modificadas
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
BR112021026002A2 (pt) Regeneração e transformação melhorada de plantas com a ajuda de um gene de reforço grf1
BRPI0513393A (pt) métodos para melhorar as caracterìsticas de crescimento de uma planta, e para produzir uma planta transgênica, planta ou célula de planta, construção, planta transgênica ou célula de planta, partes colhìveis e/ou produtos diretamente derivados das mesmas, uso de uma molécula de ácido nucleico snrk2 ou variante funcional da mesma ou uso de um polipeptìdeo snrk2 ou homólogo do mesmo, e, composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/05/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF